NEW YORK, April 6, 2011 /PRNewswire/ -- The U.S. Food and Drug Administration announced on March 31 that it had cleared Mandometer® for the treatment of patients with eating disorders.
Mandometer® is an innovative device that provides biofeedback allowing individuals to monitor their rate of eating and their development of satiety during meals and in comparison to those eating normally. Once patients learn to adapt to a normal eating pattern, they are able to normalize their body weight.
The device has been shown to be effective through randomized clinical trials for the treatment of eating disorders. Those trials have demonstrated that 75 percent of the patients treated with the Mandometer® method recover and 90 percent remain healthy over five years.
This breakthrough program was developed by Cecilia Bergh, Ph.D., and Per Sodersten, Ph.D., two researchers at the world-renowned Swedish academic health center, the Karolinska Institute in Stockholm, Sweden.
Dr. Bergh and Dr. Sodersten founded the company Mando Group AB to establish clinics that utilize the Mandometer® method to treat eating disorders. Currently, there are already Mandometer® clinics in Sweden, in Australia and one on East 78th Street in New York.
As a result of the issue of the FDA clearance, physicians can prescribe therapy by the Mandometer® method.
Cecilia Bergh is CEO of Mando Group AB and is also executive director of the Mandometer® Clinics. Per Sodersten is professor of Behavioral Neuroendocrinology at the Karolinska Institute.
To observe the Mandometer® being used, visit: http://www.mando.se/en/Media-archive--/Information-films--/Information-films-/1.aspx
Cecilia Bergh and Per Sodersten are available for interviews via phone or video satellite.